title: The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma.
abstract: OBJECTIVE
  To compare the 24-h changes of intraocular pressure (IOP) and mean ocular perfusion pressure (MOPP) obtained with tafluprost versus travoprost in patients with normal-tension glaucoma (NTG).
  
  
  METHODS
  This study is a randomized crossover study of 50 patients newly diagnosed with NTG who received either tafluprost or travoprost given once at 9 PM for 2 months, after which they were crossed over to the other medication for another 2 months. IOP and blood pressure were measured for 24 h before starting the treatment and after finishing the first and second treatment periods.
  
  
  RESULTS
  Forty-one patients completed the study. The mean (±standard deviation) 24-h IOP was 16.8±2.0 mmHg at baseline, 14.4±2.2 mmHg on tafluprost, and 13.6±1.8 mmHg on travoprost. Both prostaglandin monotherapies significantly reduced mean 24-h IOP as compared with baseline (P<0.001, P<0.001, respectively), and travoprost demonstrated a lower mean 24-h IOP than tafluprost (P=0.044). Both treatments significantly reduced the IOP from baseline at every point over 24 h. At 3 individual time points, travoprost provided a lower IOP than tafluprost: at 4 PM (13.8±2.7 vs. 14.8±2.6 mmHg, P=0.041), at 6 PM (13.5±2.5 vs. 14.4±2.5 mmHg, P=0.006), and at 8 PM (13.3±2.5 vs. 14.5±2.4 mmHg, P=0.029). Both tafluprost and travoprost significantly increased the 24-h MOPP (P=0.008, P=0.002, respectively), and travoprost demonstrated a greater 24-h MOPP than tafluprost (P=0.027).
  
  
  CONCLUSIONS
  Both tafluprost and travoprost were effective in lowering IOP and increasing MOPP throughout 24 h in NTG. However, travoprost reduced IOP greater than tafluprost in the late afternoon and evening.
authors.affiliation: 1 Department of Ophthalmology, School of Medicine, Pusan National University , Busan, Korea.
authors.forename: Jonghoon
authors.initials: J
authors.lastname: Shin
authors.forename: Ji-Woong
authors.initials: JW
authors.lastname: Lee
authors.forename: Beom-Seok
authors.initials: BS
authors.lastname: Choi
authors.forename: Eun-Young
authors.initials: EY
authors.lastname: Yun
authors.forename: Jae-Ho
authors.initials: JH
authors.lastname: Jung
authors.forename: Eun-Ah
authors.initials: EA
authors.lastname: Kim
authors.forename: Joseph
authors.initials: J
authors.lastname: Caprioli
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology; D002940:Circadian Rhythm / Q000187:drug effects*; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D057066:Low Tension Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011460:Prostaglandins F / Q000008:administration & dosage* / Q000494:pharmacology; D000069557:Travoprost
chemical_list: D000959:Antihypertensive Agents; D011460:Prostaglandins F; C485333:tafluprost; D003008:Cloprostenol; D000069557:Travoprost